|Day Low/High||0.58 / 0.61|
|52 Wk Low/High||0.61 / 1.78|
Concurrently the Company Completes Private Placement of $10 Million Convertible Notes
Multi-product facility to support the potential manufacturing of both pegunigalsidase alfa and taliglucerase alfa on a commercial scale
The Protalix medicine alidornase alfa is designed to help cystic fibrosis patients clear their lungs by making mucus thin and loose.
Positive Results in a Number of Clinically Relevant Parameters Suggest Improved Lung Function with alidornase alfa
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Shipment Size for Fourth Quarter of 2017 Represents Annual Revenues of approximately $42 Million
Approval further supports the advanced ongoing discussions with the Brazilian Ministry of Health for the supply of a significant amount of alfataliglicerase for Gaucher patients in Brazil
Six Sites Activated Across the United States and Europe with additional patients currently in the screening process for potential inclusion in trial
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.